These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 38688675)

  • 1. Repurposing of dextromethorphan as an adjunct therapy in patients with major depressive disorder: a randomised, group sequential adaptive design, controlled clinical trial protocol.
    Maji S; Mohapatra D; Jena M; Srinivasan A; Maiti R
    BMJ Open; 2024 Apr; 14(4):e080500. PubMed ID: 38688675
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Edivoxetine compared to placebo as adjunctive therapy to selective serotonin reuptake inhibitors in the prevention of symptom re-emergence in major depressive disorder.
    Oakes TM; Dellva MA; Waterman K; Greenbaum M; Poppe C; Goldberger C; Ahl J; Perahia DG
    Curr Med Res Opin; 2015 Jun; 31(6):1179-89. PubMed ID: 25894953
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Anti-inflammatory treatment of depression: study protocol for a randomised controlled trial of vortioxetine augmented with celecoxib or placebo.
    Fourrier C; Sampson E; Mills NT; Baune BT
    Trials; 2018 Aug; 19(1):447. PubMed ID: 30126458
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Simvastatin add-on to escitalopram in patients with comorbid obesity and major depression (SIMCODE): study protocol of a multicentre, randomised, double-blind, placebo-controlled trial.
    Otte C; Chae WR; Nowacki J; Kaczmarczyk M; Piber D; Roepke S; Märschenz S; Lischewski S; Schmidt S; Ettrich B; Grabe HJ; Hegerl U; Hinkelmann K; Hofmann T; Janowitz D; Junghanns K; Kahl KG; Klein JP; Krueger THC; Leicht G; Prvulovic D; Reif A; Schoettle D; Strauss M; Westermair A; Friede T; Gold SM
    BMJ Open; 2020 Dec; 10(12):e040119. PubMed ID: 33262189
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and Safety of Basimglurant as Adjunctive Therapy for Major Depression: A Randomized Clinical Trial.
    Quiroz JA; Tamburri P; Deptula D; Banken L; Beyer U; Rabbia M; Parkar N; Fontoura P; Santarelli L
    JAMA Psychiatry; 2016 Jul; 73(7):675-84. PubMed ID: 27304433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Scopolamine augmentation of a newly initiated escitalopram treatment for major depressive disorder: study protocol for a randomized controlled trial.
    Zhou J; Wang W; Yang J; Zhu X; Feng L; Xiao L; Wang G
    Trials; 2019 Jan; 20(1):33. PubMed ID: 30626409
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A double-blind, placebo-controlled study of edivoxetine as an adjunctive treatment for patients with major depressive disorder who are partial responders to selective serotonin reuptake inhibitor treatment.
    Ball S; Dellva MA; D'Souza DN; Marangell LB; Russell JM; Goldberger C
    J Affect Disord; 2014; 167():215-23. PubMed ID: 24995890
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Randomized, Double-Blind, Placebo-Controlled Trial of the mGlu2/3 Negative Allosteric Modulator Decoglurant in Partially Refractory Major Depressive Disorder.
    Umbricht D; Niggli M; Sanwald-Ducray P; Deptula D; Moore R; Grünbauer W; Boak L; Fontoura P
    J Clin Psychiatry; 2020 Jul; 81(4):. PubMed ID: 32663909
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antidepressant augmentation with metyrapone for treatment-resistant depression (the ADD study): a double-blind, randomised, placebo-controlled trial.
    McAllister-Williams RH; Anderson IM; Finkelmeyer A; Gallagher P; Grunze HC; Haddad PM; Hughes T; Lloyd AJ; Mamasoula C; McColl E; Pearce S; Siddiqi N; Sinha BN; Steen N; Wainwright J; Winter FH; Ferrier IN; Watson S;
    Lancet Psychiatry; 2016 Feb; 3(2):117-27. PubMed ID: 26727041
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intravenous administration of adenosine triphosphate and phosphocreatine combined with fluoxetine in major depressive disorder: protocol for a randomized, double-blind, placebo-controlled pilot study.
    Chen Y; Cao X; Zang W; Tan S; Ou CQ; Shen X; Gao T; Zhao L
    Trials; 2019 Jan; 20(1):34. PubMed ID: 30626424
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative efficacy of selective serotonin reuptake inhibitors (SSRI) in treating major depressive disorder: a protocol for network meta-analysis of randomised controlled trials.
    Jia Y; Zhu H; Leung SW
    BMJ Open; 2016 Jun; 6(6):e010142. PubMed ID: 27267106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomised controlled trial assessing the severity and duration of depressive symptoms associated with a clinically significant response to sertraline versus placebo, in people presenting to primary care with depression (PANDA trial): study protocol for a randomised controlled trial.
    Salaminios G; Duffy L; Ades A; Araya R; Button KS; Churchill R; Croudace T; Derrick C; Dixon P; Dowrick C; Gilbody S; Hollingworth W; Jones V; Kendrick T; Kessler D; Kounali D; Lanham P; Malpass A; Peters TJ; Riozzie D; Robinson J; Sharp D; Thomas L; Welton NJ; Wiles N; Lewis G
    Trials; 2017 Oct; 18(1):496. PubMed ID: 29065916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and tolerability of flexibly-dosed adjunct TC-5214 (dexmecamylamine) in patients with major depressive disorder and inadequate response to prior antidepressant.
    Vieta E; Thase ME; Naber D; D'Souza B; Rancans E; Lepola U; Olausson B; Szamosi J; Wilson E; Hosford D; Dunbar G; Tummala R; Eriksson H
    Eur Neuropsychopharmacol; 2014 Apr; 24(4):564-74. PubMed ID: 24507016
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of mirtazapine as add-on to paroxetine
    Xiao L; Zhu X; Gillespie A; Feng Y; Zhou J; Chen X; Gao Y; Wang X; Ma X; Gao C; Xie Y; Pan X; Bai Y; Xu X; Wang G; Chen R
    Psychol Med; 2021 May; 51(7):1166-1174. PubMed ID: 31931894
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Milnacipran and venlafaxine at flexible doses (up to 200 mg/d) in the outpatient treatment of adults with moderate-to-severe major depressive disorder: a 24-week randomised, double blind exploratory study].
    Olié JP; Gourion D; Montagne A; Rostin M; Poirier MF
    Encephale; 2009 Dec; 35(6):595-604. PubMed ID: 20004291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pooled analysis of adjunct extended-release quetiapine fumarate in patients with major depressive disorder according to ongoing SSRI or SNRI treatment.
    Bauer M; Demyttenaere K; El-Khalili N; Thase ME; Papakostas GI; Szamosi J; Earley WR; Eriksson H
    Int Clin Psychopharmacol; 2014 Jan; 29(1):16-25. PubMed ID: 24108148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Study protocol for the randomised controlled trial: antiglucocorticoid augmentation of anti-Depressants in Depression (The ADD Study).
    McAllister-Williams RH; Smith E; Anderson IM; Barnes J; Gallagher P; Grunze HC; Haddad PM; House AO; Hughes T; Lloyd AJ; McColl EM; Pearce SH; Siddiqi N; Sinha B; Speed C; Steen IN; Wainright J; Watson S; Winter FH; Ferrier IN
    BMC Psychiatry; 2013 Aug; 13():205. PubMed ID: 23914988
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomised, double-blind study in adults with major depressive disorder with an inadequate response to a single course of selective serotonin reuptake inhibitor or serotonin-noradrenaline reuptake inhibitor treatment switched to vortioxetine or agomelatine.
    Montgomery SA; Nielsen RZ; Poulsen LH; Häggström L
    Hum Psychopharmacol; 2014 Sep; 29(5):470-82. PubMed ID: 25087600
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combining mirtazapine with SSRIs or SNRIs for treatment-resistant depression: the MIR RCT.
    Kessler D; Burns A; Tallon D; Lewis G; MacNeill S; Round J; Hollingworth W; Chew-Graham C; Anderson I; Campbell J; Dickens C; Macleod U; Gilbody S; Davies S; Peters TJ; Wiles N
    Health Technol Assess; 2018 Nov; 22(63):1-136. PubMed ID: 30468145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.